ネクセラファーマの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/02/20 | 2,478 | 2,478 | 2,413 | 2,434 | -57 | -2.3% | 872,600 |
2023/02/17 | 2,570 | 2,577 | 2,471 | 2,491 | -106 | -4.1% | 1,546,400 |
2023/02/16 | 2,435 | 2,609 | 2,395 | 2,597 | +169 | +7% | 2,191,100 |
2023/02/15 | 2,340 | 2,455 | 2,305 | 2,428 | +79 | +3.4% | 1,327,400 |
2023/02/14 | 2,332 | 2,349 | 2,320 | 2,349 | +30 | +1.3% | 452,600 |
2023/02/13 | 2,326 | 2,347 | 2,291 | 2,319 | -50 | -2.1% | 686,400 |
2023/02/10 | 2,404 | 2,423 | 2,365 | 2,369 | -44 | -1.8% | 514,800 |
2023/02/09 | 2,422 | 2,434 | 2,387 | 2,413 | -24 | -1% | 530,100 |
2023/02/08 | 2,445 | 2,447 | 2,402 | 2,437 | +11 | +0.5% | 353,800 |
2023/02/07 | 2,371 | 2,435 | 2,369 | 2,426 | +57 | +2.4% | 501,200 |
2023/02/06 | 2,426 | 2,429 | 2,364 | 2,369 | -37 | -1.5% | 609,900 |
2023/02/03 | 2,421 | 2,440 | 2,392 | 2,406 | -20 | -0.8% | 692,800 |
2023/02/02 | 2,440 | 2,449 | 2,411 | 2,426 | -21 | -0.9% | 692,700 |
2023/02/01 | 2,475 | 2,519 | 2,439 | 2,447 | -5 | -0.2% | 989,200 |
2023/01/31 | 2,419 | 2,459 | 2,403 | 2,452 | +29 | +1.2% | 603,000 |
2023/01/30 | 2,405 | 2,459 | 2,398 | 2,423 | -16 | -0.7% | 605,100 |
2023/01/27 | 2,430 | 2,457 | 2,382 | 2,439 | -21 | -0.9% | 1,074,700 |
2023/01/26 | 2,445 | 2,502 | 2,431 | 2,460 | +15 | +0.6% | 952,000 |
2023/01/25 | 2,426 | 2,459 | 2,394 | 2,445 | -5 | -0.2% | 807,600 |
2023/01/24 | 2,443 | 2,470 | 2,401 | 2,450 | -25 | -1% | 1,390,800 |
2023/01/23 | 2,375 | 2,515 | 2,371 | 2,475 | +121 | +5.1% | 3,058,100 |
2023/01/20 | 2,262 | 2,364 | 2,253 | 2,354 | +114 | +5.1% | 2,513,600 |
2023/01/19 | 2,160 | 2,264 | 2,158 | 2,240 | +72 | +3.3% | 1,566,500 |
2023/01/18 | 2,122 | 2,174 | 2,084 | 2,168 | +105 | +5.1% | 1,385,300 |
2023/01/17 | 2,170 | 2,179 | 2,057 | 2,063 | -116 | -5.3% | 1,526,200 |
2023/01/16 | 2,251 | 2,268 | 2,176 | 2,179 | -85 | -3.8% | 1,143,100 |
2023/01/13 | 2,250 | 2,288 | 2,245 | 2,264 | -2 | -0.1% | 538,900 |
2023/01/12 | 2,290 | 2,299 | 2,246 | 2,266 | -17 | -0.7% | 711,000 |
2023/01/11 | 2,258 | 2,310 | 2,249 | 2,283 | +62 | +2.8% | 1,411,500 |
2023/01/10 | 2,209 | 2,249 | 2,195 | 2,221 | +4 | +0.2% | 1,035,700 |
2023/01/06 | 2,177 | 2,226 | 2,167 | 2,217 | +60 | +2.8% | 1,096,000 |
2023/01/05 | 2,148 | 2,179 | 2,113 | 2,157 | +56 | +2.7% | 1,319,900 |
2023/01/04 | 2,161 | 2,176 | 2,091 | 2,101 | -37 | -1.7% | 1,031,500 |
2022/12/30 | 2,108 | 2,158 | 2,104 | 2,138 | +43 | +2.1% | 811,700 |
2022/12/29 | 2,080 | 2,104 | 2,066 | 2,095 | +31 | +1.5% | 529,200 |
2022/12/28 | 2,070 | 2,098 | 2,034 | 2,064 | -2 | -0.1% | 836,300 |
2022/12/27 | 2,054 | 2,119 | 2,053 | 2,066 | +3 | +0.1% | 798,900 |
2022/12/26 | 2,089 | 2,098 | 2,053 | 2,063 | -46 | -2.2% | 736,600 |
2022/12/23 | 2,087 | 2,129 | 2,073 | 2,109 | +22 | +1.1% | 839,100 |
2022/12/22 | 2,091 | 2,106 | 2,056 | 2,087 | -21 | -1% | 1,009,900 |
2022/12/21 | 2,121 | 2,160 | 2,089 | 2,108 | -6 | -0.3% | 1,188,400 |
2022/12/20 | 2,141 | 2,193 | 2,079 | 2,114 | -64 | -2.9% | 1,677,700 |
2022/12/19 | 2,193 | 2,214 | 2,167 | 2,178 | -44 | -2% | 1,413,800 |
2022/12/16 | 2,161 | 2,294 | 2,157 | 2,222 | +172 | +8.4% | 5,166,900 |
2022/12/15 | 2,028 | 2,087 | 2,000 | 2,050 | +20 | +1% | 922,200 |
2022/12/14 | 2,033 | 2,083 | 2,024 | 2,030 | +6 | +0.3% | 904,900 |
2022/12/13 | 1,990 | 2,048 | 1,983 | 2,024 | +73 | +3.7% | 1,457,300 |
2022/12/12 | 1,959 | 1,969 | 1,939 | 1,951 | -32 | -1.6% | 529,300 |
2022/12/09 | 1,960 | 1,989 | 1,952 | 1,983 | +30 | +1.5% | 726,000 |
2022/12/08 | 1,945 | 1,961 | 1,928 | 1,953 | +21 | +1.1% | 596,400 |
401~
450
件表示中 / 4944件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ネクセラファーマ | 125,100円 | +197.7% | - | 0.00% | 51.12倍 | 1.63倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
ゼリア新薬 | 233,800円 | +9.6% | +17.5% | 1.97% | 13.21倍 | 1.29倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
鳥居薬 | 393,500円 | +11.1% | +20.6% | 3.05% | 23.05倍 | 0.92倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
杏林製薬 | 153,100円 | +3.2% | +4.5% | 3.40% | 17.59倍 | 0.67倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 246,000円 | +7.6% | +57.5% | 2.15% | 19.02倍 | 1.87倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム